| 前收盘价格 | 7.40 |
| 收盘价格 | 7.16 |
| 成交量 | 18,855 |
| 平均成交量 (3个月) | 36,267 |
| 市值 | 28,195,600 |
| 价格/销量 (P/S) | 3.36 |
| 股市价格/股市净资产 (P/B) | 2.94 |
| 52周波幅 | |
| 利润日期 | 26 Mar 2025 - 31 Mar 2025 |
| 营业毛利率 | -122.46% |
| 营业利益率 (TTM) | -65,066.67% |
| 稀释每股收益 (EPS TTM) | -2.62 |
| 季度收入增长率 (YOY) | -99.90% |
| 总债务/股东权益 (D/E MRQ) | 0.18% |
| 流动比率 (MRQ) | 10.68 |
| 营业现金流 (OCF TTM) | -10.72 M |
| 杠杆自由现金流 (LFCF TTM) | -5.20 M |
| 资产报酬率 (ROA TTM) | -20.34% |
| 股东权益报酬率 (ROE TTM) | -70.96% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Pulmatrix, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
-1.7
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.67 |
|
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.65% |
| 机构持股比例 | 9.01% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Highline Wealth Partners Llc | 30 Sep 2024 | 0 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合